Special Issue

The Role of Chromosomal Instability in Cancer

Message from the Guest Editor

The current Cancer Genome Project has unexpectedly thrown chromosomal instability (CIN) into the spotlight. While it is hard to identify the common recurrent gene mutation pattern for the majority of cancer types, the phenomenon of elevated CIN is overwhelming across all. Furthermore, landscapes of chromosomal or genome-level changes have better clinical prediction power than gene mutation profiles. Such facts challenge the somatic gene mutation theory of cancer and call for a search for new conceptual frameworks and technological platforms. In recent years, our understanding of cancer evolution mechanisms has undergone significant progress. The role of CIN in cancer is highly significant and deserves further timely research. Thus, this issue may include the following topics: A case study that links CIN to any hallmark of cancer.
The mechanistic study of CIN.
The study of the relationship between different types of chromosomal variations.
Studies measuring CIN.
Studies using CIN as a biomarker for prognosis and diagnosis.
Studies on the relationship between CIN and major phase transitions such as transformation, metastasis, and drug resistance.

Guest Editor

Prof. Dr. Henry H. Heng

Center for Molecular Medicine and Genomics, Pathology Department, Wayne State University School of Medicine, Detroit, MI 48201, USA

Deadline for manuscript submissions

closed (30 September 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/126617

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)